Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis.

Select Content Type
Clinical Guidelines
Authored By
DiStasio M, Chen Y, Rangachari D, Costa DB, Heher YK, VanderLaan PA
Authored On
Interests
Oncology
Pulmonology
Radiology
Speciality
Radiology
Oncology
Pulmonology
Book Detail
volume
18
ISSN
1938-0690
Publication Date
Actions
Download in App
Event Data
{"article_title":"Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP\/IASLC\/AMP Guideline Recommendations: A Single-center Analysis.","author":"DiStasio M, Chen Y, Rangachari D, Costa DB, Heher YK, VanderLaan PA","journal_title":"Clinical lung cancer","issn":"1938-0690","isbn":"","publication_date":"2017 Sep","volume":"18","issue":"5","first_page":"e349","page_count":"","accession_number":"28377205","doi":"10.1016\/j.cllc.2017.03.001","publisher":"Elsevier","doctype":"Journal Article","subjects":"Carcinoma, Non-Small-Cell Lung genetics; DNA, Neoplasm analysis; Genetic Testing statistics & numerical data; Lung Neoplasms genetics; Specimen Handling statistics & numerical data; Anaplastic Lymphoma Kinase; DNA Mutational Analysis; ErbB Receptors genet","interest_area":["Oncology"," Pulmonology"," Radiology"],"abstract":"Introduction: Molecular testing to identify targetable driver mutations is the standard of care for patients with advanced-stage non-small cell lung cancer. Recent guideline recommendations by the College of American Pathologists (CAP), International Asso","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=28377205&authtype=shib&custid=ns346513","isPdfLink":true,"isSAML":false,"additionalInfo":{"Authored_By":"DiStasio M, Chen Y, Rangachari D, Costa DB, Heher YK, VanderLaan PA","Journal_Info":"Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0690 (Electronic) Linking ISSN: 15257304 NLM ISO Abbreviation: Clin Lung Cancer Subsets: MEDLINE","Publication_Type":"Journal Article","Published_Date":"2017-09-01","Source":"Clinical lung cancer [Clin Lung Cancer] 2017 Sep; Vol. 18 (5), pp. e349-e356. Date of Electronic Publication: 2017 Mar 14.","Languages":"English","Electronic_ISSN":"1938-0690","MeSH_Terms":"Carcinoma, Non-Small-Cell Lung\/*genetics , DNA, Neoplasm\/*analysis , Genetic Testing\/*statistics & numerical data , Lung Neoplasms\/*genetics , Specimen Handling\/*statistics & numerical data, Anaplastic Lymphoma Kinase ; DNA Mutational Analysis ; ErbB Receptors\/genetics ; Feasibility Studies ; Female ; Genetic Testing\/standards ; Humans ; In Situ Hybridization, Fluorescence ; Male ; Molecular Targeted Therapy ; Practice Guidelines as Topic ; Protein-Tyrosine Kinases\/genetics ; Proto-Oncogene Proteins\/genetics ; Proto-Oncogene Proteins p21(ras)\/genetics ; Receptor Protein-Tyrosine Kinases\/genetics ; Retrospective Studies ; Specimen Handling\/standards ; Time Factors ; Workflow","Subjects":"Anaplastic Lymphoma Kinase, DNA Mutational Analysis, ErbB Receptors genetics, Feasibility Studies, Female, Genetic Testing standards, Humans, In Situ Hybridization, Fluorescence, Male, Molecular Targeted Therapy, Practice Guidelines as Topic, Protein-Tyrosine Kinases genetics, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins p21(ras) genetics, Receptor Protein-Tyrosine Kinases genetics, Retrospective Studies, Specimen Handling standards, Time Factors, Workflow, Carcinoma, Non-Small-Cell Lung genetics, DNA, Neoplasm analysis, Genetic Testing statistics & numerical data, Lung Neoplasms genetics, Specimen Handling statistics & numerical data","Title_Abbreviations":"Clinical lung cancer","Volume":"18"},"header":{"DbId":"mdl","DbLabel":"MEDLINE Ultimate","An":"28377205","RelevancyScore":"808","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"808.320617675781"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=28377205&authtype=shib&custid=ns346513&group=main&profile=eds","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=28377205&authtype=shib&custid=ns346513&group=main&profile=eds"}
ISSN
1938-0690
IS_Ebsco
true
Upload Link
https://search.ebscohost.com/login.aspx?direct=true&db=mdl&AN=28377205&authtype=shib&custid=ns346513
Additional Info
["DiStasio M, Chen Y, Rangachari D, Costa DB, Heher YK, VanderLaan PA","Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0690 (Electronic) Linking ISSN: 15257304 NLM ISO Abbreviation: Clin Lung Cancer Subsets: MEDLINE","Journal Article","2017-09-01","Clinical lung cancer [Clin Lung Cancer] 2017 Sep; Vol. 18 (5), pp. e349-e356. Date of Electronic Publication: 2017 Mar 14.","English","1938-0690","Carcinoma, Non-Small-Cell Lung\/*genetics , DNA, Neoplasm\/*analysis , Genetic Testing\/*statistics & numerical data , Lung Neoplasms\/*genetics , Specimen Handling\/*statistics & numerical data, Anaplastic Lymphoma Kinase ; DNA Mutational Analysis ; ErbB Receptors\/genetics ; Feasibility Studies ; Female ; Genetic Testing\/standards ; Humans ; In Situ Hybridization, Fluorescence ; Male ; Molecular Targeted Therapy ; Practice Guidelines as Topic ; Protein-Tyrosine Kinases\/genetics ; Proto-Oncogene Proteins\/genetics ; Proto-Oncogene Proteins p21(ras)\/genetics ; Receptor Protein-Tyrosine Kinases\/genetics ; Retrospective Studies ; Specimen Handling\/standards ; Time Factors ; Workflow","Anaplastic Lymphoma Kinase, DNA Mutational Analysis, ErbB Receptors genetics, Feasibility Studies, Female, Genetic Testing standards, Humans, In Situ Hybridization, Fluorescence, Male, Molecular Targeted Therapy, Practice Guidelines as Topic, Protein-Tyrosine Kinases genetics, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins p21(ras) genetics, Receptor Protein-Tyrosine Kinases genetics, Retrospective Studies, Specimen Handling standards, Time Factors, Workflow, Carcinoma, Non-Small-Cell Lung genetics, DNA, Neoplasm analysis, Genetic Testing statistics & numerical data, Lung Neoplasms genetics, Specimen Handling statistics & numerical data","Clinical lung cancer","18"]
Description
Introduction: Molecular testing to identify targetable driver mutations is the standard of care for patients with advanced-stage non-small cell lung cancer. Recent guideline recommendations by the College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) established a benchmark turnaround time (TAT) target of 10 working days for results to be available to the treating oncologist and ≤ 3 days for specimens to arrive at a commercial testing laboratory if testing is not performed in-house.<br />Methods and Materials: To provide insights regarding the pre-testing, post-testing, and testing intervals that constitute the overall TAT target, we performed a detailed workflow analysis. A total of 157 lung cancer specimens were sent out for molecular testing at a commercial vendor from a single academic medical center during the calendar year 2015.<br />Results: Overall, 128 specimens (81.5%) met the recommended 10-working day TAT, with a median total TAT of 9 weekdays (mean ± standard deviation, 9.17 ± 4.15 days). The pre-testing interval was ≤ 3 days for 146 specimens (93.0%), and the post-testing reporting interval was &lt; 1 day for 116 cases (73.9%). The TAT variance was not related to intrinsic specimen characteristics.<br />Conclusion: Overall, the findings indicated that the CAP/IASLC/AMP TAT guideline recommendations are feasible for most lung cancer specimens when a streamlined system is in place.<br /> (Copyright © 2017 Elsevier Inc. All rights reserved.)
Published Date